Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If we are giving investment advice - wo to those who tread that path - put your AXIM money in a jar in the backyard - even with JB's -8% cash growth plan, you'll be better off
I'm not going to be a cheerleader, and I'm not going to make any predictions.
However, if someone had new money and wanted to open a new position in AXIM, this would be my recommendation.
Hold on to your money for awhile longer. Even if AXIM starts selling these Dry Eye Disease tests it will take some time for sales to ramp up. Additionally the share price will take some time to follow the earnings growth.
In other words, if AXIM really does become successful eventually with these Dry Eye Disease tests, it won't happen tomorrow or next week. It make take 2 or 3 quarters of sales results for investors to appreciate the business again.
Bottom line, AXIM has hired some very smart eye doctors/surgeons and successful business owners in the Dry Eye Disease segment. This is not a scam, but currently AXIM has no cashflow. Investors will have to wait awhile for AXIM cashflow to show up on the Quarterly Reports.
Is there no scientific credibility for the 4 DED tests and the testing accuracy? Why is it specifically that this would be known to be a scam? I think there is a need for accurate testing for DED. It is not always an easy disease to diagnose. Paradoxically many patients experience excessive tearing.
I agree however that the price performance of the stock is consistent with how a scam stock would perform if investors thought it was a scam.
BesaoT35, you do know this is a scam, right? Even the squirrels have left this stinking shit / sinking ship. It was a scam from the beginning, is and ever shall be. Amen.
The Market Cap is around $9 million. What sort of annual DED test sales could be in the ballpark for AXIM? If sales were growing rapidly what sort of pps could be justified? Thanks
Maybe AXIM gets a discount from the accounting firm when they file late?
I've grown to expect that filing. I was reading it waiting for the last line regarding the narrative.
Dragon can't do anything to get the PPS back up. Anyone that reads the 10K knows this is just another penny stock scam. The volume has evaporated....the end is near.
Hey AXIM Are a FEW weeks up yet? Put down the Coffee and get to work .
The end is near for this stock.....
You can't use the internet in Club Fed
Janey maybe hard of seeing rodent can become a pitchman for Phoenix Power Solutions. I hear they are looking for ethical staff.
Bought more. Can't help myself. Call the Addiction Center.
$0.068
+$0.0015
you know when your price changes are quoted in 1/10s of a penny - you're phukt
Could the last person to leave the room please dry their tears and turn off the lights. Immunopass now sounds something like an annual bus pass in Italy for seniors!
my logic: fool me once shame on me, fool me twice shame on me again
SCAM!
Janey you might be somewhat premature calling this a scam. However the changing narrative as to income potential and return to shareholders is what clouded the picture. One product was to bring in huge amounts of money and of course subsequent rise in the shareholder prize but now the narrative is back to this company being in its infancy and blah blah blah blah blah-the usual get in early as they add windows, buy more when doors are added, and back up the truck now the roof is on. Before that it seemed the company tent was providing a healthy return but now of course the narrative has shifted away from that to give them more time. So Immunopass which was to save the share price and upend medical research is done like dinner and being replaced with another product line. As soon as investors begin prematurely talking about massive returns on the investment that is the time to sell into the sweeping rhetoric. Take advantage of any created AXIM momentum on sp and volume. Always remember on stocks like AXIM that volume validates price, not the other way around. AXIM is just another OTC pink pharma.
Lol, "You can lead a person through logic, but you can't make them think."
When you construct a building, initially you have to spend money on materials and labor. There is no revenue generation at this time.
When you sell the building, the revenues come in and hopefully, if you did things right, the revenues more than offset the cost of manufacturing.
Are you suggesting that during the building process, the project should be considered a "scam"?
Can you see the faulty logic you are using?
"You have to spend money in order to make money."
Clearly you have the right to call it whatever you want, but using that wrong word shows a complete lack of business knowledge.
In the hands of someone with that mentality, a brokerage account could personally be a very dangerous thing.
Best of luck in your future endeavors.
SCAM until someone showws the money
this could easily go sub-penny; there is NO VALUE here - some promise of futures revs a year+ out? yeah, heard that before
Another nice find, thanks again Tex.
I watched a few times, your quote depicts what is said accurately.
If you listen carefully, it is very clear that the "reporter" is just reading off a prompter without any knowledge of what she is saying. At first she talks about MMP-9, then talks about the reader measuring Lactoferrin levels.
Yes, the reader is good for all 4 tests, but the way she presents it is a bit confusing.
Still, no publicity is bad publicity.
Little by little, the word will get out.
Godspeed.
"Two tests will be available in 2nd quarter. Each test will cost $21 and will be insurance reimbursable."
Quote may not be exact, but video is only 2 minutes long. The date shows this to have been released a week or two ago, but not sure it has been shared yet.
https://eyewire.news/tv/axim-biotechnologies-to-launch-rapid-quantitative-tear-tests-for-ded-biomarkers
I'm going to agree with you on this point.
We have to see some revenue or the price may keep dropping.
Today maybe...but in next year with no revenues I expect this to hit 1 cent, maybe less.
Lets see how this plays out
Now that the Fed is done for May and the investor letter has been absorbed we will see what AXIM is worth with the information that is out there regarding DED and the Cancer products. I'm looking for the next input from market action rather than the company. The pressure seems to be off today but time will tell.
Actually, maybe I didn’t miss speak, I meant total scam
Bad investment, nah, scam, yes
"Scam" is the wrong word.
Using it shows a lack of logic, investing finesse, emotional maturity.
Better would be to use "bad investment", and use facts to justify your position (which, truthfully, at the present time, you could make a definitive argument for your case).
But there is zero evidence of any "scam".
By using the word "scam" to describe Axim, you are just discrediting anything else that you might say in your post that might have a shred of credibility.
right right right - show some revs and all is forgiven - until then = SCAM
Excellent analysis.
Yes, higher volume of shares, but that is just because the pps is so much lower. Generally speaking, on any given day, the dollar amount traded is probably about the same.
I also believe the disappointment with the failure of the long-shot, "Immunopass" FDA approval has soured many on the potential of Axim. Thinking back, we were all posting about Immunopass while John H and Axim were pulling the entire DED line of products and the accompanying board together.
We were all talking Immunopass while Axim was putting out press release after press release relating to the Dry Eye Disease line.
Thank God John H and Axim did so (but of course, they had a much better understanding of the FDA approval process and the politics behind it), and shame on us for wearing our rosy colored glasses and not being able to read between the lines and seeing what they (Axim and John H) were clearing saying.
So, in all honesty, it is the investors who were focused on the wrong product (Immunopass and not DED) that are responsible for the current disappointment and the very low pps right now.
Unfortunately, I believe this will continue for the entire summer and on into the fall (figure 6 to 7 months or so), as most Axim investors feel they have been "burned" and misled, and will no longer invest based on "potential." They are now looking for solid results (ie: revenues).
If, as I believe, Axim is selling shares to pay for current operating costs (outstanding shares is recently up from 136 million to 152 million), then that dilution process should cease a few months before we share holders are aware of the progress (ie: we won't believe that sales/revenues are actually occurring until we see solid proof of it on a quarterly report, which comes out a month and a half after the activity in that quarter finishes).
To summarize: I believe sales revenues will begin towards the end of this (the second) quarter, be reported on the 10-Q of 8/15 but will be insignificant, and will continue and grow throughout the 3rd quarter (to the point that revenues will offset the need to raise capital by selling shares), and will be reported on the 10-Q of 11/15 (after the midterms).
I believe that the 3rd quarter 10-Q (11/15) will begin to give some shareholders the solid proof that they are looking for.
Hence my belief that the pps won't start to right itself until sometime after the midterms.
In other words, I believe Axim is way over sold right now, and if I had dry powder, I too would seek to take advantage of investor pessimism.
JMHO (and please, do read my disclaimer below).
Godspeed.
There is no doubt that a lot more volume right now can be generated with a lot less money pushing that volume.
AXIM is what it is.
The current price action is from the huge disappointment from #ImmunoPass not being approved by the FDA.
All future price action will be focused on the DED segment producing sales and cashflow (or not).
Obviously there are some investors who are disappointed in the past failure and are not fully sold on the potential of a DED future.
I do think the DED future can be profitable, but I still have no idea when the sales will actually start.
It makes sense to be cautious right now. On the other hand, if there is true value for AXIM & investors in the Dry Eye Disease segment then it is much better to buy low and sell at a higher price.
I still have some shares in other accounts from different price points. I may have to hang onto those for awhile. Any new money invested in AXIM would be "Dry Eye Disease" money in a different account. I would not need to Dollar Cost Average for AXIM in that account.
Looking for dry powder.
Anyway. Good luck to everyone.
Nothing but high volume, lower lows, and maybe a bounce (hopefully not just a dead cat bounce) possibly forming yesterday/today.
Let's see if it holds.
I'm trying to catch up.
Was anything reported this week?
I have not seen any news since the 4th DED test was announced on 4-27. Has something else been reported?
Thanks in advance!
BTW:
If I get a little bit of dry powder, I plan to start a new position in a new account soon. Especially if I can grab some cheap shares under 10 cents. I don't plan a large position, but I would like to hopefully flip some future AXIM gains into other longer term holds. My focus on AXIM at this point (this price level) is to harvest some short-term gains from this level to maybe 50 cents or 75 cents a share.
Fairly accurate call today, as AXIM traded mostly above yesterday's close for almost the entire day.
Let's hope your prediction continues.
So what did those at Axim gain in this elaborate scam?
I think "projected" revenues is more accurate than "promised".
I further believe that the individuals at Axim have much more to gain when revenues begin than any one of the investors here on this board.
I don't think it can be called a "scam". I don't think anyone actively "scammed" anyone out of their hard earned money. Were you contacted directly from someone at Axim, that used some kind of selling pressure to get you to buy the stock?
Maybe you can personally see it as a "bad investment", but you have to be mature enough to take responsibility for your own mistakes.
NO ONE forced you to invest in Axim.
Investing in Axim was your own decision, and investing in anything has inherent risks.
BTW....please do read my disclaimer at the bottom of my posts.
Because they have beeen promising revs but have no revs and will have no revs for how long ... ? Yeah, a scam
I am wondering if you think AXIM is a "scam", and if so, what is the actual purpose of the scam?
Do you think that there are entire companies out there, that pull top notch experts in their fields together, just to have people buy their stock with the goal of making them lose money?
Total scam - DED is how many months from revs ... ? like COVID testes were .... ?
yeah, a scam.
Agree with you janeyH. So mad at myself for putting my hard earned money here. Only hope is for revenue on dry eye tests...seems like that will never happen. Until proven otherwise with revenues...this is a scam!
That's an interesting take and quite possibly correct. I would like to see John do another San Diego ABC 10 interview soon. The investor letter is very clear but I would like to see him present the material. The videos were so upbeat until the last one where he looked like he wasn't feeling well. I thought that it was a personal issue then but now it seems that he had business concerns.
I think its because the copmany sux
I'm certain there are a whole slue of factors that have contributed to making this transition period so challenging. This is quite a politically charged environment. Moving from an entirely R&D company to a company now focusing on product sales is certain to have its ups and downs. New territory for Axim at this time.
Not to say that this period hasn't been rough for many others, even well established companies.
Fortunately, I personally can still see a path to success through the forest, but that path is neither straight nor smooth, and although I can't now see the way out of the jungle, I do know it is there and is achievable.
I guess I am judging John and Axim by how they have navigated the hardships to date, and how they have adjusted to obstacles in their way.
I keep putting myself in John's shoes, and think to myself what I would have done, and even with the little knowledge that I have of what is going on inside Axim, I seem to gravitate towards the same decisions.
Its like the creation of a piece of art. You start with a lump of clay or a blank canvas. As time progresses, the clay begins to take shape or the paint is added to the canvas, but even looking at it part-way the piece of art might look like mayhem.
Patience. Let it form. Some can see the final result very early on in the process, whereas others can't see it until the final product, but in all instances, the final product is awe inspiring.
Personally, I think that is how Axim is progressing. Give it time. Rough season ahead, as this summer is destined to be filled with political as well as financial turmoil, but by end of year (after the mid-term elections), I think we are going to see a major turn around.
Godspeed.
It has been a rough Spring for AXIM. I don't know if it is due to John's chrystal clear investor letter and its discussion of the FDA rejection or if it was driven by the Federal Reserve's plan to increase the Federal Funds Rate to 3% in December with a half point increase today at 2PM Eastern with the next increase planned the first week of June. Jerome Powell has been very clear about his plans and there are many references to his recent speaches on the internet.
Bounce coming. $AXIM
Followers
|
105
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5296
|
Created
|
04/29/14
|
Type
|
Free
|
Moderators Blue Skys Squirrel Hunter |
Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovixTM differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes.
“We are hopeful our test fills an important need in these uncertain times. While other tests merely show whether someone was infected with coronavirus, we took it a step further by creating a test that stratifies individuals into those who have neutralizing antibodies, which are essential in preventing reinfection, and those who don’t. The test can be deployed for point of care use in convalescent plasma transfusions to severely ill patients and for evaluating efficacy of upcoming vaccines in generating protective antibodies,” said Sergei Svarovsky, PhD, MBA, AXIM’s CSO and co-inventor of NeuCovixTM.
An immediate application of NeuCovixTM, a point-of-care test, is to measure levels of neutralizing antibodies in convalescent plasma so that plasma with the highest levels of neutralizing antibodies can be identified and administered to patients fighting COVID-19. Without this knowledge, many patients could be undertreated with non-neutralizing plasma and may not benefit from this treatment.
Another application of NeuCovixTM is to help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ the NeuCovixTM rapid, point-of-care test to evaluate protective immune responses in vaccine recipients.
AXIM® Biotech CEO John W. Huemoeller II commented, “Our goal was to make this test, accurate, fast and relatively inexpensive so it could serve as an ‘Immunity Passport port™’ for vaccine developers around the world as they begin larger Phase II and III clinical trials. We are optimistic that NeuCovixTM will be widely used, becoming the gold standard in assessing levels of immunity.”
Doug Lake, Ph.D. and co-inventor of NeuCovixTM commented, “Everybody who recovers from COVID-19 makes antibodies against the virus, but since all antibodies are not created equal, you really want to know if the antibodies you make neutralize the virus. People who recover want to make sure they are protected from re-infection and that they won’t infect others.”
AXIM also announced the filing of a pre-Emergency Use Authorization Application (EUA) and has already initiated dialogue with the FDA in order to finalize its EUA submission. The intellectual property relating to the novel serological test is the subject of Provisional Patent Application No. 63/023,646 “Convalescent Plasma Testing and Treatment” filed on May 12, 2020.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses for oncological therapeutics. For more information, please visit www.AXIMBiotech.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |